Author: claimsbot

1. A structural ballistic panel member comprising:
a) a front plate having an outward surface and an inward surface, the front plate further having first and second lateral areas,
b) a ballistic portion comprised of a ballistic fabric layer adhesively attached to the rearward surface of the front plate,
c) first and second lateral wall members attached to the first and second lateral areas of the front plate,
d) a tension plate attached to the first and second lateral wall members,
e) a chamber region defined in part by the first and second lateral wall members, the tension plate and the ballistic portion,
f) a closed cell rigid structural foam positioned within the chamber region having a foam density between 1-10 pounds per cubic foot.
2. The structural ballistic panel member as recited in claim 1 where the chamber region is substantially enclosed and the foam material is foamed in place providing a pressure in the chamber region that is greater than atmospheric pressure.
3. The structural ballistic panel member as claim 2 where the foam material adheres to an inner surface of the ballistic portion providing a backing to increase the ballistic properties of the ballistic portion.
4. The structural ballistic panel member as recited in claim 1 where the front plate is a metallic plate.
5. The structural ballistic panel member as recited in claim 4 where the front plate is an aluminum plate less than \xbc of an inch in thickness.
6. The structural ballistic panel member as recited in claim 4 where the front plate is an aluminum plate less than \u215c of an inch in thickness.
7. The structural ballistic panel member as recited in claim 1 where the ballistic portion is comprised of at least 5 layers of ballistic fabric connected by an adhesive.
8. The structural ballistic panel member as recited in claim 1 with the foam material is in direct contact with an inner surface of the first and second lateral wall members.
9. The structural ballistic panel member as recited in claim 1 where the ballistic portion is comprised of at least 15 layers of ballistic fabric connected by an adhesive.
10. The structural ballistic panel member as recited in claim 8 where the foam material is in direct contact with the tension plate.
11. The structural ballistic panel member as recited in claim 1 where the first and second lateral regions of the front plate define overlapping interface regions that are operatively configured to connect to an adjacent overlapping interface region of an adjacent structural ballistic panel member.
12. The structural ballistic panel member as recited in claim 1 where the structural ballistic panel member is positioned within the hull portion of a boat and the front plate is an outer portion of a boat hull.
13. The structural ballistic panel member as recited in claim 1 where the foam region is at least a 90% closed-cell rigid polyurethane or polyisocyanurate foam.
14. The protective panel as recited in claim 13 where the ballistic material is adhered to the inner surface of the front panel by way of an adhesive which is mixed with a fiber.
15. The protective panel as recited in claim 15 where the fiber in the adhesive has the thermal property of reducing heat transfer to the ballistic material more so than if the fiber was not used.
16. The structural ballistic panel member as recited in claim 13 where the foam layer is operatively configured to receive a projectile that passes through the ballistic portion.
17. The structural ballistic panel member as recited in claim 16 where the foam layer is operatively configured to reduce the velocity of the projectile and divert the projectile’s initial course before impacting the structural ballistic panel.
18. A projectile stopping system configured to stop the level 3 ballistic threat from a projectile, the projectile stopping system comprising:
a) an encasement having a front wall and a rear wall and a first and second lateral walls,
b) a ballistic resistant material positioned adjacent to the front wall and adhered thereto,
c) a closed cell rigid structural foam positioned within the chamber region which is foamed in place, creating a slight positive pressure in the chamber region above atmospheric pressure,
d) whereas the ballistic resistant material is properly configured to allow a level 3 ballistic threat to pass therethrough and the closed cell rigid structural foam is configured to de-accelerate the projectile sufficiently prior to the projectile exiting the rear wall of the encasement.
19. The projectile stopping system as recited in claim 18 where the rear wall is a sheet of ballistic material.
20. The projectile stopping system as recited in claim 19 where the ballistic material is either Kevlar, Spectra or Dyneema.
21. The projectile stopping system as recited in claim 18 where the closed cell rigid structural foam is at least 92% closed cell.
22. A protective panel operatively configured to stop at least a level III ballistic threat from a projectile, the protective panel comprising:
a) a substantially enclosed encasement and a front wall and a rear wall and a perimeter wall,
b) a ballistic resistant material positioned adjacent to the front wall and a closed cell foam foamed in place and adhered to a rearward surface of the ballistic resistant material,
c) whereas the closed cell foam is configured to de-accelerate a projectile sufficiently prior to the projectile passing through the rear wall of the substantially enclosed encasement and the ballistic resistant material is configured to allow a ballistic threat which is greater than level III to pass therethrough to enter the closed cell foam.
23. The protective panel as recited in claim 22 where the closed cell foam is at least 1 inch in thickness behind the ballistic resistant material.
24. The protective panel as recited in claim 22 where the protective panel is comprised of aluminum.
25. The protective panel as recited in claim 22 where a second layer of ballistic resistant material is positioned in the foam.
26. The protective panel as recited in claim 23 where the closed cell foam is no more than 6 inches in thickness behind the ballistic resistant material.
27. The protective panel as recited in claim 26 where the protective panel is a portion of a hull of a boat.
28. The protective panel as recited in claim 22 where the ballistic material is adhered to the inner surface of the front panel by way of an adhesive which is mixed with a fiber.
29. The protective panel as recited in claim 28 where the fiber in the adhesive has the thermal property of reducing heat transfer to the ballistic material more so than if the fiber was not used.
30. The protective panel as recited in claim 29 where the fiber in the adhesive is Kevlar.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A hitting device comprising a ball-less mode, a resting mode wherein a ball is resting on a cup, and a secure mode wherein the ball is releasably held to the cup comprising:
a) a pedestal having a cup; and
b) a resilient strap attached to the hitting device, the resilient strap releasably holds the ball to the cup under the force of the resilient strap’s resiliency;
wherein the hitting device is in the ball-less mode when no ball is resting on the cup, the hitting device is in the resting mode when the ball is held on the cup substantially by the force of gravity only, and the hitting device is in the secure mode when the resilient strap is holding the ball releasably on the cup.
2. The device in claim 1, further comprising a stem disposed below the pedestal.
3. The device in claim 2, wherein the stem is telescopic.
4. The device as in claim 2, further comprising a base disposed below the stem.
5. The device in claim 4, wherein the base is weight-fillable for stabilizing the base.
6. The device in claim 5, further comprising at least one location member for positioning the pedestal at various locations associated with the base.
7. The device in claim 2, further comprising a flex member disposed below the stem for allowing the stem to flex.
8. The device in claim 7, further comprising a base disposed below the flex member.
9. The device in claim 8, wherein the base is weight-fillable for stabilizing the base.
10. The device in claim 8, wherein the stem is telescopic.
11. The device in claim 10, wherein the base is weight-fillable for stabilizing the base.
12. The device in claim 1, wherein the resilient strap is an elastic band.
13. A hitting device comprising a ball-less mode, a resting mode wherein a ball is resting on a cup, and a secure mode wherein the ball is releasably held to the cup comprising:
a) a pedestal having a cup; and
b) a resilient strap attached to the pedestal, the resilient strap releasably holds the ball to the cup under the force of the resilient strap’s resiliency; and
c) a stem disposed below the pedestal;
wherein the hitting device is in the ball-less mode when no ball is resting on the cup, the hitting device is in the resting mode when the ball is held on the cup substantially by the force of gravity only, and the hitting device is in the secure mode when the resilient strap is holding the ball releasably on the cup.
14. The device in claim 13, wherein the stem is telescopic.
15. The device as in claim 14, further comprising a base disposed below the stem.
16. The device in claim 15, wherein the base is weight-fillable for stabilizing the base.
17. The device in claim 16, further comprising at least one location member for positioning the pedestal at various locations associated with the base.
18. The device in claim 13, further comprising a flex member disposed below the stem for allowing the stem to flex.
19. The device in claim 18, further comprising a base disposed below the flex member.
20. The device in claim 19, wherein the base is weight-fillable for stabilizing the base.
21. The device in claim 19, wherein the stem is telescopic.
22. The device in claim 21, wherein the base is weight-fillable for stabilizing the base.
23. The device in claim 13, wherein the resilient strap is an elastic band.
24. A hitting device comprising a ball-less mode, a resting mode wherein a ball is resting on a cup, and a secure mode wherein the ball is releasably held to the cup comprising:
a) a pedestal having a cup;
b) a resilient strap attached to the hitting device, the resilient strap releasably holds the ball to the cup under the force of the resilient strap’s resiliency;
c) a telescopic stem disposed below the pedestal;
d) a flex member disposed below the stem for allowing the stem to flex; and
e) a base disposed below the flex member;
wherein the hitting device is in the ball-less mode when no ball is resting on the cup, the hitting device is in the resting mode when the ball is held on the cup substantially by the force of gravity only, and the hitting device is in the secure mode when the resilient strap is holding the ball releasably on the cup.
25. The device in claim 24, wherein the base is weight-fillable for stabilizing the base.
26. The device in claim 24, further comprising at least one location member for positioning the pedestal at various locations associated with the base.
27. The device in claim 24, wherein the resilient strap is an elastic band.

1. A method comprising:
receiving search criteria, the search criteria comprising one or more interests;
normalizing, using one or more computer processors, the one or more interests;
selecting, using the one or more computer processors, one or more second users of the social network who meet the search criteria, the selecting of each second user being based on: (1) the one or more normalized interests, (2) the interests of the second user, and (3) an estimated probability of each pair of interests, each pair including a first interest from the one or more normalized interests and a second interest from the interests of the second user; and
transmitting information associated with the one or more second users.
2. The method of claim 1, wherein the selecting is based on an interest compatibility score for each pair of interests.
3. The method of claim 2, wherein the interest compatibility score for a pair of interests is based on the estimated probability calculated for the pair of interests divided by the product of the estimated probability calculated for a first interest of the pair of interests and the estimated probability calculated for a second interest of the pair of interests.
4. The method of claim 1, wherein the search criteria is received in relation to a first user of a social network.
5. The method of claim 1, wherein the search criteria is received in relation to a third-party website, application, or web service.
6. The method of claim 1, wherein each of the one or more second users are connected to the first user within the social network.
7. The method of claim 1, further comprising determining, for each of the one or more second users of the social network, an interest compatibility score between the first user and the second user, wherein the transmitted information associated with the second user comprises the interest compatibility score between the first user and the second user.
8. A method comprising:
calculating, using one or more computer processors, an interest compatibility score between each of one or more pairs of interests, the interest compatibility score for each pair of interests being based on the estimated probability of the pair of interests;
receiving search criteria from a user of a social network, the search criteria comprising a first interest;
determining one or more compatible interests, wherein each compatible interest has an interest compatibility score in relation to the first interest that exceeds a pre-determined threshold;
retrieving, using the one or more computer processors, search results based on the search criteria and the one or more compatible interests, the search results comprising information associated with one or more other users of the social network, each of the one or more other users having at least one interest of the one or more compatible interests; and
transmitting the search results to the user.
9. The method of claim 8, wherein the search criteria is received in relation to a first user of a social network.
10. The method of claim 8, wherein the search criteria is received in relation to a third-party website, application, or web service.
11. One or more computer-readable non-transitory storage media embodying logic that is operable when executed to:
receive search criteria, the search criteria comprising one or more interests;
normalize, using one or more computer processors, the one or more interests;
select, using the one or more computer processors, one or more second users of the social network who meet the search criteria, the selection of each second user being based on: (1) the one or more normalized interests, (2) the interests of the second user, and (3) an estimated probability of each pair of interests, each pair including a first interest from the one or more normalized interests and a second interest from the interests of the second user; and
transmit information associated with the one or more second users.
12. The media of claim 11, wherein the selection is based on an interest compatibility score for each pair of interests.
13. The method of claim 12, wherein the interest compatibility score for a pair of interests is based on the estimated probability calculated for the pair of interests divided by the product of the estimated probability calculated for a first interest of the pair of interests and the estimated probability calculated for a second interest of the pair of interests.
14. The media of claim 11, wherein the search criteria is received in relation to a first user of a social network.
15. The media of claim 11, wherein the search criteria is received in relation to a third-party website, application, or web service.
16. The media of claim 11, wherein each of the one or more second users are connected to the first user within the social network.
17. The media of claim 11, further embodying logic that is operable when executed to determine, for each of the one or more second users of the social network, an interest compatibility score between the first user and the second user, wherein the transmitted information associated with the second user comprises the interest compatibility score between the first user and the second user.
18. A system, comprising:
one or more non-transitory machine-readable storage media encoded with instructions; and
one or more processors operable to execute the instructions to:
receive search criteria, the search criteria comprising one or more interests;
normalize the one or more interests;
select one or more second users of the social network who meet the search criteria, the selection of each second user being based on: (1) the one or more normalized interests, (2) the interests of the second user, and (3) an estimated probability of each pair of interests, each pair including a first interest from the one or more normalized interests and a second interest from the interests of the second user; and
transmit information associated with the one or more second users.
19. The system of claim 18, wherein the selection is based on an interest compatibility score for each pair of interests, the interest compatibility score for a pair of interests being based on the estimated probability calculated for the pair of interests divided by the product of the estimated probability calculated for a first interest of the pair of interests and the estimated probability calculated for a second interest of the pair of interests.
20. The system of claim 18, wherein the one or more processors are further operable to determine, for each of the one or more second users of the social network, an interest compatibility score between the first user and the second user, wherein the transmitted information associated with the second user comprises the interest compatibility score between the first user and the second user.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

What is claimed is:

1. An isolated nucleic acid molecule consisting of a polynucleotide having a nucleotide sequence selected from the group consisting of:
(a) a polynucleotide fragment of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284;
(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161, which is hybridizable to SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284;
(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161 which is hybridizable to SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284;
(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161, which is hybridizable to SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284;
(e) a polynucleotide encoding a polypeptide of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161 which is hybridizable to SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284, having NFkB modulating activity;
(f) a polynucleotide which is a variant of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284;
(g) a polynucleotide which is an allelic variant of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284;
(h) a polynucleotide which encodes a species homologue of the SEQ ID NO:109-118, 126, 128, 144-152, or 160-161;
(i) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284;
(j) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(i), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment consisting of a nucleotide sequence encoding a NFkB modulatory protein, or fragment thereof.
3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment consisting of a nucleotide sequence encoding the sequence identified as SEQ ID NO:109-118, 126, 128, 144-152, or 160-161, which is hybridizable to SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284.
4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment consisting of the entire nucleotide sequence of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284, which is hybridizable to SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284.
5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence consisting of sequential nucleotide deletions from either the C-terminus or the N-terminus.
6. An isolated polypeptide consisting an amino acid sequence selected from the group consisting of:
(a) a polypeptide fragment of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161;
(b) a polypeptide fragment of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161, capable of modulating an NFkB response;
(c) a polypeptide domain of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161;
(d) a polypeptide epitope of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161;
(e) a full length protein of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161;
(f) a variant of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161;
(g) an allelic variant of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161; and
(h) a species homologue of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161.
7. The isolated polypeptide of claim 6, wherein the the full length protein consists sequential amino acid deletions from either the C-terminus or the N-terminus.
8. An isolated antibody that binds specifically to the isolated polypeptide of claim 6.
9. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 6.
10. A method of diagnosing a NFkB associated condition or a susceptibility to a NFkB associated condition in a subject wherein said condition is a member of the group consisting of an immune disorder; an inflammatory disorder in which polypeptides of the present invention are associated with the disorder either directly; or indirectly; an inflammatory disorder related to aberrant NFkB regulation; a cancer; aberrant apoptosis; hepatic disorders; Hodgkins lymphomas; hematopoietic tumors; hyper-IgM syndromes; hypohydrotic ectodermal dysplasia; X-linked anhidrotic ectodermal dysplasia; Immunodeficiency; al incontinentia pigmenti; viral infections; HIV-1; HTLV-1; hepatitis B; hepatitis C; EBV; influenza; viral replication; host cell survival; and evasion of immune responses; rheumatoid arthritis inflammatory bowel disease; colitis; asthma; atherosclerosis; cachexia; euthyroid sick syndrome; stroke; EAE; autoimmune disorders; disorders related to hyper immune activity; disorders related to aberrant acute phase responses; hypercongenital conditions; birth defects; necrotic lesions; wounds; organ transplant rejection; conditions related to organ transplant rejection; disorders related to aberrant signal transduction; proliferating disorders; cancers; and HIV propagation in cells infected with other viruses; comprising:
(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and
(b) diagnosing a NFkB associated condition or a susceptibility to a NFkB associated condition based on the presence or absence of said mutation, wherein said mutation indicates a predisposition to at least one of said NFkB associated disorders
11. A method of diagnosing an NFkB associated condition or a susceptibility to a NFkB associated condition in a subject wherein said condition is a member of the group consisting of an immune disorder; an inflammatory disorder in member of the group consisting of an immune disorder; an inflammatory disorder in which polypeptides of the present invention are associated with the disorder either directly, or indirectly; an inflammatory disorder related to aberrant NFkB regulation; a cancer; aberrant apoptosis; hepatic disorders; Hodgkins lymphomas; hematopoietic tumors; hyper-IgM syndromes; hypohydrotic ectodermal dysplasia; X-linked anhidrotic ectodermal dysplasia; Immunodeficiency; al incontinentia pigmenti; viral infections; HIV-1; HTLV-1; hepatitis B; hepatitis C; EBV; influenza; viral replication; host cell survival; and evasion of immune responses; rheumatoid arthritis inflammatory bowel disease; colitis; asthma; atherosclerosis; cachexia; euthyroid sick syndrome; stroke; EAE; autoimmune disorders; disorders related to hyper immune activity; disorders related to aberrant acute phase responses; hypercongenital conditions; birth defects; necrotic lesions; wounds; organ transplant rejection; conditions related to organ transplant rejection; disorders related to aberrant signal transduction; proliferating disorders; cancers; and HIV propagation in cells infected with other viruses, comprising:
(a) determining the presence or amount of expression of the polypeptide of claim 6 in a biological sample; and
(b) diagnosing a NFkB associated condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
12. A method for identifying a binding partner to the polypeptide of claim 6 comprising:
(a) contacting the polypeptide of claim 6 with a binding partner; and
(b) determining whether the binding partner effects an activity of the polypeptide.
13. The method for preventing, treating, or ameliorating a medical condition of claim 9, wherein the medical condition is a member of the group consisting of an immune disorder; an inflammatory disorder in which polypeptides of the present invention are associated with the disorder either directly; or indirectly; an inflammatory disorder related to aberrant NFkB regulation; a cancer; aberrant apoptosis; hepatic disorders; Hodgkins lymphomas; hematopoietic tumors; hyper-IgM syndromes; hypohydrotic ectodermal dysplasia; X-linked anhidrotic ectodermal dysplasia; Immunodeficiency; al incontinentia pigmenti; viral infections; HIV-1; HTLV-1; hepatitis B; hepatitis C; EBV; influenza; viral replication; host cell survival; and evasion of immune responses; rheumatoid arthritis inflammatory bowel disease; colitis; asthma; atherosclerosis; cachexia; euthyroid sick syndrome; stroke; EAE; autoimmune disorders; disorders related to hyper immune activity; disorders related to aberrant acute phase responses; hypercongenital conditions; birth defects; necrotic lesions; wounds; organ transplant rejection; conditions related to organ transplant rejection; disorders related to aberrant signal transduction; proliferating disorders; cancers; and HIV propagation in cells infected with other viruses.
14. A method of identifying a compound that modulates the biological activity of a NFkB associated molecule, comprising:
(a) combining a candidate modulator compound with a NFkB associated molecule having the sequence set forth in a member of the group consisting of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161, or a polypeptide encoded by a polynucleotide selected from the group consisting of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284; and
(b) measuring an effect of the candidate modulator compound on the activity of the NFkB associated molecule.
15. A method of identifying a compound that modulates the biological activity of an NFkB associated molecule, comprising:
(a) combining a candidate modulator compound with a host cell expressing a NFkB associated molecule having the sequence as set forth in a member of the group consisting of SEQ ID NO:109-118, 126, 128, 144-152, or 160-161, or a polypeptide encoded by a polynucleotide selected from the group consisting of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284; and
(b) measuring an effect of the candidate modulator compound on the activity of the expressed NFkB associated molecule.
16. A method of identifying a compound that modulates the biological activity of a NFkB associated molecule, comprising:
(a) combining a candidate modulator compound with a host cell containing a vector comprising the polynucleotide sequence selected from the group consisting of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284, wherein a NFkB associated molecule is expressed by the cell; and
(b) measuring an effect of the candidate modulator compound on the activity of the expressed NFkB associated molecule.
17. A method of screening for a compound that is capable of modulating the biological activity of a NFkB associated molecule, comprising the steps of:
(a) providing a host cell containing a vector comprising the polynucleotide sequence selected from the group consisting of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, or 264-284;
(b) determining the biological activity of the NFkB associated molecule in the absence of a modulator compound;
(c) contacting the cell with the modulator compound; and
(d) determining the biological activity of the NFkB associated molecule in the presence of the modulator compound; wherein a difference between the activity of the NFkB associated molecule in the presence of the modulator compound and in the absence of the modulator compound indicates a modulating effect of the compound.
18. A compound that modulates the biological activity of a human NFkB associated molecule as identified by the method according to a member of the group consisting of: the compound(s) identified according to the method of claim 14; the, compound(s) identified according to the method of claim 15; the compound(s) identified according to the method of claim 16; and the compound(s) identified according to the method of claim 17.
19. The method of claim 10 further comprising the use of probes or primer pairs specific to a member of the group consisting of: (i) a polynucleotide encoding a polypeptide fragment of a member of the group consisting of SEQ ID NO:109-118, 126, 128, 144-152, 160, and 161; (ii) a polynucleotide encoding a polypeptide domain of a member of the group consisting of SEQ ID NO:109-118, 126, 128, 144-152, 160, and 161; (iii) a polynucleotide encoding a polypeptide epitope of a member of the group consisting of SEQ ID NO:109-118, 126, 128, 144-152, 160, and 161; (iv) a polynucleotide encoding a polypeptide of a member of the group consisting of SEQ ID NO:109-118, 126, 128, 144-152, 160, and 161 having NFkB modulating activity; (v) a polynucleotide encoding a polypeptide of a member of the group consisting of SEQ ID NO:109-118, 126, 128, 144-152, 160, and 161 which is modulated by NFkB or the NFkB pathway; (vi) a polynucleotide which represents the complimentary sequence (antisense) of a member of the group consisting of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, and 264-284; (vii) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified herein, wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues; (viii) an isolated nucleic acid molecule of a member of the group consisting of SEQ ID NO:109-118, 126, 128, 144-152, 160, and 161, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a NFkB associated protein; (ix) an isolated nucleic acid molecule of a member of the group consisting of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, and 264-284, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as a member of the group consisting of SEQ ID NO:109-118, 126, 128, 144-152, 160, and 161, which is hybridizable to SEQ ID NO:1-108, 125, 127, 132-140, 158-159, and 264-284; and (x) an isolated nucleic acid molecule of of a member of the group consisting of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, and 264-284, wherein the polynucleotide fragment comprises the entire nucleotide sequence of a member of the group consisting of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, and 264-284; wherein said method comprises the step of using said probe or primer pair to correlate expression of said member to a disease or disorder associated with said member.
20. The method of claim 11 comprising an antibody directed against a member of the group consisting of: SEQ ID NO:109-118, 126, 128, 144-152, 160, and 161, or encoded by the polynucleotide selected from the group consisting of SEQ ID NO:1-108, 125, 127, 132-140, 158-159, and 264-284.